ms and glp 1 Denaturing gel electrophoresis (SDS-PAGE) LC-MS showing the Q&A 111: Glucagon-like peptide-1 receptor – GLP-1s and Multiple Sclerosis -

Dont be

The anti-inflammatory pathways modulated by GLP-1 receptor activation (NF-kB suppression, macrophage polarization, Treg enhancement) are largely distinct from the pathways targeted by: Methotrexate: Folate metabolism disruption, different anti-inflammatory pathway TNF inhibitors (adalimumab, etanercept): Direct TNF blockade, whereas GLP-1 reduces TNF production upstream IL-6 inhibitors (tocilizumab): Receptor-level blockade, while GLP-1 reduces IL-6 production JAK inhibitors (tofacitinib, baricitinib): Different signaling pathway entirely Corticosteroids: Broad immunosuppression, while GLP-1 is immunomodulatory This pathway complementarity is why additive benefit is biologically plausible

Participants will receive weekly injections of either a GLP-1 or a placebo for 28 weeks

Individuals allergic to any kind of vitamin